Daniel Bradbury

Board Chairman

Dan Bradbury has served as Chairman of the Castle Biosciences Board of Directors since September 2014, and as a director since 2008. He is a life sciences executive with over 30 years of experience creating and implementing strategies that transform businesses, bring novel medicines to market and maximize shareholder value. He is the Managing Member of BioBrit, LLC, a life sciences consulting and investment firm.

Dan is the former President, Chief Executive Officer and Director of Amylin Pharmaceuticals, a biopharmaceutical company focused on metabolic diseases. During his 18-year tenure at Amylin, the company launched three first-in-class medicines, including the first once-a-week therapy to treat diabetes, and was listed on the Nasdaq 100. He served as Amylin’s CEO from March 2007 until its acquisition by Bristol-Myers Squibb for $7 billion in 2012. Before joining Amylin, Mr. Bradbury worked in marketing and sales roles for ten years at SmithKline Beecham Pharmaceuticals. He also serves on the Boards of Directors of Corcept Therapeutics, Geron Corporation, Illumina, Inc., as well as the Board of Trustees of the Keck Graduate Institute, the Investor Growth Capital Advisory Board, and the BioMed Ventures Advisory Committee.

Mr. Bradbury currently serves on the University of California San Diego’s Rady School of Management’s Advisory Council, the RAND Health Board of Advisors and the University of Miami’s Innovation Corporate Advisory Council. He received a Bachelor of Pharmacy from Nottingham University and a Diploma in Management Studies from Harrow and Ealing Colleges of Higher Education in the United Kingdom.

Derek Maetzold

Founder, President and CEO, Director

A leader in the biopharmaceutical industry for the past 25 years, Derek Maetzold founded Castle Biosciences in 2007 and has successfully overseen the discovery, development and commercialization of five diagnostic and prognostic tests in cancers, with more in the pipeline. Derek founded the Company after a career of successive leadership roles at Encysive Pharmaceuticals, Schering Corporation (now Merck), Integrated Communications, Amylin Pharmaceuticals (now AstraZeneca) and Sandoz (now Novartis).

Derek started in field sales, and has served in roles that span the disciplines of marketing, new product development, business development, and commercialization strategy. Previously, he served as Officer and Vice President, Marketing and Sales, at Encysive Pharmaceuticals. He attended George Mason University, where he received a B.S. in Biology, and completed additional coursework at the University of Calgary Health Sciences Center and the MBA program at University of California-Riverside. Derek is a published author, and a co-inventor of a number of technologies at Castle Biosciences and Encysive Pharmaceuticals.

Bonnie H. Anderson


Bonnie H. Anderson is the cofounder of Veracyte (Nasdaq: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, where she serves as president and chief executive officer.

Ms. Anderson’s career spans nearly 30 years in the diagnostics and life sciences markets. She cofounded Veracyte in 2008, spearheaded its successful initial public offering in 2013 and has led its commercialization efforts to date. These include the introduction of Veracyte’s first product, the Afirma® Thyroid FNA Analysis, which is becoming a new standard of care in thyroid cancer diagnosis. The company also recently entered the pulmonology market with the launch of Percepta Bronchial Genomic Classifier to help reduce unnecessary invasive procedures in lung cancer diagnosis. Prior to Veracyte, Ms. Anderson provided strategic consulting services to venture capital firms and early-stage businesses following 18 years in various leadership roles at Beckman Coulter, a biomedical laboratory instruments company.

Ms. Anderson is a trustee emeritus of the Keck Graduate Institute of Applied Life Sciences and holds a B.S. in Medical Technology from Indiana University of Pennsylvania. In 2012, the university honored her with a “Distinguished Alumni” award. In 2015, she was featured in Fast Company’s “100 Most Creative People in Business,” and in 2014 was named one of the “Bay Area’s Most Admired CEOs” by the San Francisco Business Times.

Mara Aspinall


Mara Aspinall is the former President and CEO of Ventana Medical Systems, a member of the Roche Group—a worldwide leader in the development, manufacturing and commercialization of tissue-based cancer diagnostic products that enable personalized healthcare to patients. During her tenure, Ventana became the world’s leading oncology companion diagnostics developer and manufacturer.

Previously, Ms. Aspinall spent 12 years with Genzyme Corporation where she was President of Genzyme Genetics and President of Genzyme Pharmaceuticals. She was also the Founder, CEO and Director of On-Q-ity, a diagnostic company focused on transforming cancer patient management through the capture of circulating tumor cells (CTCs) in a patient’s blood.

A dynamic participant in the life sciences community, Ms. Aspinall has spearheaded many initiatives to educate policymakers about diagnostics and personalized medicine. Most recently, she co-founded the International School of Biomedical Diagnostics at Arizona State University and Dublin City University, the first school dedicated to Diagnostics as an independent discipline. She also founded DxInsights, an institute committed to expanding knowledge on the importance of diagnostics in improving patient care, as well as the European Personalized Medicine Association (EPEMED), and acted as a former Director of the U.S. Personalized Medicine Coalition (PMC).

Ms. Aspinall has served on several committees throughout her career, including 15 years on the Board of the Dana Farber Cancer Institute, chairing the Science Committee, Blue Cross Blue Shield Massachusetts, and the Secretary of Health and Human Services’ Advisory Council on Genetics for both the Obama and Bush Administrations. Today, Ms. Aspinall chairs the Arizona Biosciences Board, a group led by CEOs in multiple industries dedicated to improving the state’s atmosphere for technology companies.

Ms. Aspinall holds an MBA from Harvard Business School and a BA in International Relations from Tufts University.

Joseph C. Cook, Jr.


Joe Cook has served as a director for Castle Biosciences, Inc. since 2008. He is a principal and co-founder of Mountain Group Capital. He is a founder and former Chairman of the Board of Ironwood Pharmaceuticals, Inc., where he continues to serve as a Director. He also serves as a director of Corcept Therapeutics, Inc.

Joe served as Chairman of Amylin Pharmaceuticals, Inc. from 1998 to 2009 and was Chief Executive Officer from 1998 to 2003. In 2009, Joe received the Pinnacle Award for Life Science Leadership from the Rady School of Management at the University of California at San Diego.

Joe retired as a Group Vice President, Global Operations, of Eli Lilly and Company in 1993 after more than 28 years of service. During his career at Lilly he served in various senior executive positions, including manufacturing, engineering, finance, sales and marketing and general management. Joe took a leave of absence from Eli Lilly and Co. in 1976 and was employed by the U.S. International Trade Commission in Washington, D.C. as a part of the President’s Executive Exchange Program.

Joe serves as Chairman of the Board of Mercy Ministries International, Inc. He is also a former Chair and current member of the University of Tennessee College of Engineering Advisory Board. In 1999, Joe received the Nathan W. Dougherty Award from the University of Tennessee for distinguished service in the engineering profession. Joe also serves on the national board of the American Diabetes Association and is Chairman of the Board of Life Science Tennessee. He also serves as Chairman of Diabetes Care Group and on the Board of Clinical Products. He was a co-founder and serves on the boards of Device Innovation Group and Diagnovus.

Joe graduated from the University of Tennessee in 1965 where he received a B.S. in Engineering with High Honors and was a U.T. Torchbearer.

Garheng Kong, M.D., Ph.D.


Dr. Kong has served as a director for Castle Biosciences, Inc. since 2014. He is the founder and Managing Partner of HealthQuest Capital, a healthcare focused investment firm, and has been a healthcare investor since 2000. He was a General Partner at Sofinnova Ventures and Intersouth Partners. Dr. Kong has served as chairman and director on the boards of numerous companies, and operated as interim CEO for two venture-backed companies. Specifically, he served as the founding investor and Chairman of Cellective Therapeutics (acquired by AstraZeneca), Chairman of Serenex (acquired by Pfizer), Chairman of Novamin Technologies (acquired by GlaxoSmithKline), Chairman of Cempra Pharmaceuticals, and lead investor of the first financing for Alimera Sciences. Dr. Kong has also led investments in Viamet Pharmaceuticals (Chairman), Proteon Therapeutics, Applied Genetic Technology Corporation, TransEnterix, Calibra Medical (acquired by J&J), Athenix (acquired by Bayer, board observer), Aldagen (acquired by Cytomedix), Histogenics (Chairman), Salveo Specialty Pharmacy, SARcode Bioscience Inc. (acquired by Shire) and First Aid Beverages, Inc. Additionally he sits on the board of Laboratory Corporation of America and the Duke University Medical Center Board of Visitors.

Dr. Kong serves or has served on the boards of directors of the SEBIO organization, the North Carolina Biotechnology Center, the Council for Entrepreneurial Development (CED), the Hamner Institutes for Life Sciences, the North Carolina Medical Device Organization, the University of Florida Biotechnology Council, the University of Virginia Ivy Foundation, the Pennsylvania Life Sciences Greenhouse, the Southeast Universities Research Association, the Investor Advisory Board for the Florida Institute for the Commercialization of Public Research, Corporate Chaplains of America and the Duke Medical Center Institutional Review Board (IRB).

Prior to his investing career, Dr. Kong spent time at GlaxoSmithKline, McKinsey & Company, and TherOx. He received his M.D. (Medical Scientist Training Program), Ph.D. in Biomedical Engineering, and M.B.A. from Duke University, where he also served on the faculty. He also holds B.S. degrees in Chemical Engineering and Biological Sciences from Stanford University.